/ Reports / Europe Leber Congenital Amaurosis M...

Europe Leber Congenital Amaurosis Market - Industry Trends and Forecast to 2029

author

Data Bridge Market Research

date

2 years ago

delivery time

1 business day

Europe leber congential amaurosis market is projected to register a CAGR of 5.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029
 

Market Segmentation: 
Europe Leber Congenital Amaurosis Market, By Disease (Infantile Type, Juvenile Type and Other), Type (Therapy and Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe) Industry Trends and Forecast to 2029


Some of the major factors contributing to the growth of the Europe leber congential amaurosis market are:

• Genetic advances in the diagnosis of LCA
 

• Rising chronic disease

 

Market Players:

 

The key market players for Europe leber congential amaurosis market are listed below:

• Invitae Corporation
• Spark Therapeutics, Inc. 
• CENTOGENE N.V.
• Allergan
• CENTOGENE N.V.
• Novartis AG

Licenses

$

Report Actions

Reviews

5

1 reviews

06 May 2022

Douglas Insights Internal Team Evaluation of this publisher

5

Report Quality

5

Money Value

5

Support

5

Request a sample
or customization

Inquiry before buying